GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncorus Inc (OTCPK:ONCR) » Definitions » PEG Ratio

Oncorus (Oncorus) PEG Ratio : N/A (As of May. 03, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Oncorus PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Oncorus's PE Ratio without NRI is 0.00. Oncorus's 5-Year EBITDA growth rate is 0.00%. Therefore, Oncorus's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Oncorus's PEG Ratio or its related term are showing as below:



ONCR's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.525
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Oncorus PEG Ratio Historical Data

The historical data trend for Oncorus's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncorus PEG Ratio Chart

Oncorus Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
PEG Ratio
- - - - -

Oncorus Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Oncorus's PEG Ratio

For the Biotechnology subindustry, Oncorus's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncorus's PEG Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncorus's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Oncorus's PEG Ratio falls into.



Oncorus PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Oncorus's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


Oncorus  (OTCPK:ONCR) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Oncorus PEG Ratio Related Terms

Thank you for viewing the detailed overview of Oncorus's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncorus (Oncorus) Business Description

Traded in Other Exchanges
N/A
Address
4 Corporate Drive, Andover, MA, USA, 01810
Oncorus Inc is a preclinical-stage biopharmaceutical company focused on the intravenous administration of self-amplifying RNA to transform outcomes for cancer patients. The company is in the process of developing intratumorally and intravenously administered product candidates designed to selectively attack and kill tumor cells and stimulate multiple arms of the immune system against tumors. Its pipeline product includes ONCR-021 and ONCR-788 which are based on coxsackievirus A21 or CVA21, and Seneca Valley Virus, or SVV, respectively.
Executives
Brian J. Shea officer: Interim CEO C/O ONCORUS, INC., 4 CORPORATE DRIVE, ANDOVER MA 01810
Alexander Nolte officer: Interim CFO 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
James E Flynn director, 10 percent owner, other: *Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Douglas Fambrough director C/O DICERNA PHARMACEUTICALS, INC., 75 HAYDEN AVENUE, LEXINGTON MA 02421
Rick Wanstall officer: CFO and Treasurer C/O AILERON THERAPEUTICS, INC., 490 ARSENAL WAY, WATERTOWN MA 02472
Stephen Harbin officer: COO and Chief of Staff C/O ONCORUS, INC., 50 HAMPSHIRE STREET, SUITE 401, CAMBRIDGE MA 02139
Barbara Yanni director 1018 W. 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Eric Rubin director C/O ONCORUS, INC., 50 HAMPSHIRE STREET, SUITE 401, CAMBRIDGE MA 02139
Christophe Queva officer: CSO and SVP, Research C/O ONCORUS, INC., 50 HAMPSHIRE STREET, SUITE 401, CAMBRIDGE MA 02139
Scott A Canute director FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Mpm Bioventures 2014, L.p. 10 percent owner C/O MPM ASSET MANAGEMENT LLC, 450 KENDALL STREET, CAMBRIDGE MA 02142
Luke Evnin director, 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH STREET, BOSTON MA 02116
Oncology Impact Fund (cayman) Management L.p. 10 percent owner 450 KENDALL STREET, CAMBRIDGE MA 02142
Mpm Asset Management Investors Sunstates Fund Llc 10 percent owner 450 KENDALL STREET, CAMBRIDGE MA 02142
Ansbert Gadicke 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116

Oncorus (Oncorus) Headlines

From GuruFocus

Oncorus to Present at the Jefferies Global Healthcare Conference

By GuruFocusNews GuruFocusNews 06-21-2022

Oncorus to Present at the Jefferies Global Healthcare Conference

By GuruFocusNews GuruFocusNews 06-11-2022

Oncorus to Present at the H.C. Wainwright Global Investment Conference

By GuruFocusNews GuruFocusNews 07-06-2022

Oncorus to Present at the H.C. Wainwright Global Investment Conference

By GuruFocusNews GuruFocusNews 05-17-2022

Oncorus Appoints Douglas Fambrough to Board of Directors

By GuruFocusNews GuruFocusNews 07-03-2022

Oncorus to Present at the H.C. Wainwright Global Investment Conference

By GuruFocusNews GuruFocusNews 06-16-2022